# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Oppenheimer initiates Vaxart coverage with an Outperform rating and $4 price target, citing a bullish outlook on its oral vacci...
Oppenheimer initiates coverage on Vaxart (NASDAQ:VXRT) with a Outperform rating and announces Price Target of $4.
Vaxart, a clinical-stage biotechnology company developing a range of oral recombinant vaccines, announced Monday that proceeds ...
— Cash runway extended into 2026 — — Received one of the largest BARDA-funded Project NextGen Awards to date, up to $453 millio...
Vaxart (VXRT) shares surged 23% in premarket session after receiving a $453 million project award from BARDA to conduct a COVID...